Validation of Patient Determined Disease Steps (PDDS) scale scores in persons with multiple sclerosis

BMC Neurology (Impact Factor: 2.04). 04/2013; 13(1):37. DOI: 10.1186/1471-2377-13-37
Source: PubMed


The Patient Determined Disease Steps (PDDS) is a promising patient-reported outcome (PRO) of disability in multiple sclerosis (MS). To date, there is limited evidence regarding the validity of PDDS scores, despite its sound conceptual development and broad inclusion in MS research. This study examined the validity of the PDDS based on (1) the association with Expanded Disability Status Scale (EDSS) scores and (2) the pattern of associations between PDDS and EDSS scores with Functional System (FS) scores as well as ambulatory and other outcomes.

96 persons with MS provided demographic/clinical information, completed the PDDS and other PROs including the Multiple Sclerosis Walking Scale-12 (MSWS-12), and underwent a neurological examination for generating FS and EDSS scores. Participants completed assessments of cognition, ambulation including the 6-minute walk (6 MW), and wore an accelerometer during waking hours over seven days.

There was a strong correlation between EDSS and PDDS scores (ρ = .783). PDDS and EDSS scores were strongly correlated with Pyramidal (ρ = .578 &ρ = .647, respectively) and Cerebellar (ρ = .501 &ρ = .528, respectively) FS scores as well as 6 MW distance (ρ = .704 &ρ = .805, respectively), MSWS-12 scores (ρ = .801 &ρ = .729, respectively), and accelerometer steps/day (ρ = -.740 &ρ = -.717, respectively).

This study provides novel evidence supporting the PDDS as valid PRO of disability in MS.

Download full-text


Available from: Yvonne C Learmonth, Oct 08, 2015
11 Reads
  • Source
    • "Participants arrived at the Colorado Translational Research Imaging Center during the morning hours following an 8 h fast, and patients with MS were assessed for disability levels utilizing the Patient Determined Disease Steps (PDDS). The PDDS has been validated and shows a high correlation to the Expanded Disability Status Scale (EDSS) (Hohol et al., 1995, 1999; Kobelt et al., 2006; Learmonth et al., 2013; Marrie and Goldman, 2007). Leg spasticity was graded using the MASS. "
    [Show abstract] [Hide abstract]
    ABSTRACT: Difficulties in ambulation are one of the main problems reported by patients with multiple sclerosis. A previous study by our research group showed increased recruitment of muscle groups during walking, but the influence of skeletal muscle properties, such as muscle fiber activity, has not been fully elucidated. The purpose of this investigation was to use the novel method of calculating glucose uptake heterogeneity in the leg muscles of patients with multiple sclerosis and compare these results to healthy controls. Eight patients with multiple sclerosis (4 men) and 8 healthy controls (4 men) performed 15min of treadmill walking at a comfortable self-selected speed following muscle strength tests. Participants were injected with≈8mCi of [(18)F]-fluorodeoxyglucose during walking after which positron emission tomography/computed tomography imaging was performed. No differences in muscle strength were detected between multiple sclerosis and control groups (P>0.27). Within the multiple sclerosis, group differences in muscle volume existed between the stronger and weaker legs in the vastus lateralis, semitendinosus, and semimembranosus (P<0.03). Glucose uptake heterogeneity between the groups was not different for any muscle group or individual muscle of the legs (P>0.16, P≥0.05). Patients with multiple sclerosis and healthy controls showed similar muscle fiber activity during walking. Interpretations of these results, with respect to our previous study, suggest that walking difficulties in patients with multiple sclerosis may be more associated with altered central nervous system motor patterns rather than alterations in skeletal muscle properties. Published by Elsevier Ltd.
    Clinical biomechanics (Bristol, Avon) 12/2014; 30(2). DOI:10.1016/j.clinbiomech.2014.12.005 · 1.97 Impact Factor
  • Source
    • "The Patient-Determined Disease Steps (PDDS) score, relapse history, and symptom worsening are routinely collected in NARCOMS surveys. The PDDS is a validated 9-point self-report measure, which correlates highly with the expanded disability status scale (EDSS).10–12 It is an ordinal scale ranging from 0 (normal, reference group) to 8 (bedbound). "
    [Show abstract] [Hide abstract]
    ABSTRACT: IntroductionThe evolving landscape of disease-modifying therapies (DMTs) for multiple sclerosis raises important questions about why patients change DMTs. Physicians and patients could benefit from a better understanding of the reasons for switching therapy.PurposeTo investigate the reasons patients switch DMTs and identify characteristics associated with the decision to switch.MethodThe North American Research Committee on Multiple Sclerosis (NARCOMS) Registry conducted a supplemental survey among registry participants responding to the 2011 update survey. The supplemental survey investigated reasons for switching DMT, origin of the discussion of DMT change, and which factors influenced the decision. Chi-square tests, Fisher’s exact tests, and logistic regression were used for the analyses.ResultsOf the 691 eligible candidates, 308 responded and met the inclusion criteria (relapsing disease course, switched DMT after September 2010). The responders were 83.4% female, on average 52 years old, with a median (interquartile range) Patient-Determined Disease Steps score of 4 (2–5). The most recent prior therapy included first-line injectables (74.5%), infusions (18.1%), an oral DMT (3.4%), and other DMTs (4.0%). The discussion to switch DMT was initiated almost equally by physicians and participants. The primary reason for choosing the new DMT was based most frequently on physician’s recommendation (24.5%) and patient perception of efficacy (13.7%).ConclusionParticipants frequently initiated the discussion regarding changing DMT, although physician recommendations regarding the specific therapy were still weighed highly. Long-term follow-up of these participants will provide valuable information on their disease trajectory, satisfaction with, and effectiveness of their new medication.
    Patient Preference and Adherence 07/2014; 8:971-9. DOI:10.2147/PPA.S49903 · 1.68 Impact Factor
  • Source
    • "The PDDS is a patient-reported measure that is scored ordinally from 0 (no disability) to 8 (bedbound) [11]. It has been shown to correlate well with the neurologist scored EDSS (r = 0.78; p = 0.0001) [12]; and both measures have been used by clinicians and researchers to assess MS-related disease severity and progression. "
    [Show abstract] [Hide abstract]
    ABSTRACT: Background Limited data define what constitutes a minimal clinically important difference (MCID) on the EuroQol 5-Dimension (EQ-5D) health status index in persons with multiple sclerosis (PwMS). We sought to estimate the MCID for the EQ-5D health index in North American PwMS. Methods PwMS completing the Patient Determined Disease Steps (PDDS) scale, 12-Item Multiple Sclerosis Walking Scale (MSWS-12) and EQ-5D as part of the North American Research Committee on Multiple Sclerosis (NARCOMS) registry’s spring 2011 update and supplemental survey were included in this retrospective, cross-sectional study. Distribution-based (standard error of measurement [SEM], 0.50 standard deviation [SD] and 0.33 SD unit) approaches were used to estimate a range of MCIDs for the EQ-5D based upon disease severity groups determined by the PDDS and MSWS-12 tertiles. Results A total of 3,044 participants were included. Moderately strong correlations between the EQ-5D and the PDDS and MSWS-12 were observed (Spearman’s r = -0.56 and -0.59, respectively, p < 0.0001 for both). MCID estimates based on PDDS score categories ranged from 0.065-0.158 (SEMs), 0.059-0.142 (0.50 SDs) and 0.039-0.095 (0.33 SDs). MCID estimates as measured by MSWS-12 tertile categories ranged from 0.068-0.098 (SEMs), 0.061-0.088 (0.50 SDs), and 0.041-0.059 (0.33 SDs). Across both the PDDS and tertiles of MSWS-12, MCID estimates tended to be larger as disease severity worsened. Mean weighted MCID estimates ranged from 0.05-0.084 for both the PDDS and MSWS-12 tertiles. Conclusion MCID estimates for the EQ-5D in PwMS were within the range of estimates seen for other disease states and appeared to be larger in those reporting more severe disease.
    Health and Quality of Life Outcomes 05/2014; 12(1):66. DOI:10.1186/1477-7525-12-66 · 2.12 Impact Factor
Show more